Aminosalicylic acid: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) |
||
| Line 30: | Line 30: | ||
==Mechanisms of Action== | ==Mechanisms of Action== | ||
Aminosalicylic acid is an analogue of [[para-aminobenzoic acid|para-aminobenzoic acid (PABA)]] and acts as a competitive inhibitor of [[dihydropteroate synthetase|dihydropteroate synthase 1 (folP1)]]. Its competitive antagonism with PABA is similar to the action of [[sulfonamides]] which disrupts biosynthesis in sensitive organisms. Aminosalicylic acid is [[bacteriostatic]] against ''[[Mycobacterium tuberculosis]]''. It inhibits the onset of bacterial resistance to [[streptomycin]] and [[isoniazid]]. Other mechanism of action has been postulated to be inhibition of synthesis of the cell wall component, mycobactin, thus reducing iron uptake by ''[[M. tuberculosis]]''. | Aminosalicylic acid is an analogue of [[para-aminobenzoic acid|para-aminobenzoic acid (PABA)]] and acts as a competitive inhibitor of [[dihydropteroate synthetase|dihydropteroate synthase 1 (folP1)]]. Its competitive antagonism with PABA is similar to the action of [[sulfonamides]] which disrupts biosynthesis in sensitive organisms. Aminosalicylic acid is [[bacteriostatic]] against ''[[Mycobacterium tuberculosis]]''. It inhibits the onset of bacterial resistance to [[streptomycin]] and [[isoniazid]]. Other mechanism of action has been postulated to be inhibition of synthesis of the cell wall component, mycobactin, thus reducing iron uptake by ''[[M. tuberculosis]]''. | ||
Revision as of 22:02, 25 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Aminosalicylic acid (also known as para-aminosalicylic acid, p-aminosalicylic acid or 4-aminosalicylic acid; abbreviated 4-ASA, or PAS) is an antibiotic used to treat tuberculosis. It has been use for over forty years in the treatment of inflammatory bowel diseases (IBDs), where it has shown greater potency in Crohn's disease. It is thought to act via NF-κB (nuclear factor-kappa B) inhibition and free radical scavenging.
Aminosalicylic acid is sold in the United States by Jacobus Pharmaceutical as PASER®. Mesalazine (5-aminosalicylic acid) is a closely related compound that also has medical uses.
Category
Antimycobacterial
US Brand Names
PASER®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanisms of Action
Aminosalicylic acid is an analogue of para-aminobenzoic acid (PABA) and acts as a competitive inhibitor of dihydropteroate synthase 1 (folP1). Its competitive antagonism with PABA is similar to the action of sulfonamides which disrupts biosynthesis in sensitive organisms. Aminosalicylic acid is bacteriostatic against Mycobacterium tuberculosis. It inhibits the onset of bacterial resistance to streptomycin and isoniazid. Other mechanism of action has been postulated to be inhibition of synthesis of the cell wall component, mycobactin, thus reducing iron uptake by M. tuberculosis.